SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'ps'
ALIM (Alimera Sciences) PS Ratio
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alimera Sciences's share price is $3.57.
Alimera Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.32. Hence, Alimera Sciences's PS Ratio for today is 0.67.
Warning Sign:
Alimera Sciences Inc stock PS Ratio (=1.12) is close to 3-year high of 1.19
The historical rank and industry rank for Alimera Sciences's PS Ratio or its related term are showing as below:
ALIM'
s PS Ratio Range Over the Past 10 Years
Min: 0.17 Med: 1.6 Max: 903.53
Current: 0.66
During the past 13 years, Alimera Sciences's highest PS Ratio was 903.53. The lowest was 0.17. And the median was 1.60.
ALIM's PS Ratio is ranked better than 82.9% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.17
vs ALIM: 0.66
Alimera Sciences's Revenue per Sharefor the
three
months ended in Dec. 2023 was $0.50.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.32.
Warning Sign:
Alimera Sciences Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Alimera Sciences was -59.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -31.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -15.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.40% per year.
During the past 13 years, Alimera Sciences's highest 3-Year average Revenue per Share Growth Rate was 122.20% per year. The lowest was -31.70% per year. And the median was 4.75% per year.
Back to Basics: PS Ratio
Alimera Sciences PS Ratio Historical Data
The historical data trend for Alimera Sciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Alimera Sciences Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
PS Ratio
0.67
0.42
0.57
0.35
1.37
Alimera Sciences Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
PS Ratio
0.35
0.26
0.36
0.45
1.37
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alimera Sciences PS Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's PS Ratio falls into.
Alimera Sciences PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Alimera Sciences's PS Ratio for today is calculated as
Alimera Sciences's Share Price of today is $3.57.
Alimera Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Alimera Sciences PS Ratio Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Alimera Sciences (Alimera Sciences) Business Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALIM has been successfully added to your 